Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib-Reference-Cited by-同舟云学术

Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib

Published:2023-09 Issue:9 Volume:19 Page:786-792
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

Dagogo-Jack Ibiayi¹²^ORCID,Manoogian Amanda³,Jessop Nicholas⁴,Georgantas N. Zeke⁴,Fintelmann Florian J.²⁵^ORCID,Farahani Alexander⁴,Digumarthy Subba R.²⁵,Price Melissa C.²⁵,Folch Erik E.²⁶,Keyes Colleen M.²⁶^ORCID,Do Andrew¹^ORCID,Peterson Jennifer L.¹,Mino-Kenudson Mari²⁷^ORCID,Pitman Martha²⁷,Rivera Miguel²⁴^ORCID,Nardi Valentina²⁴,Dias-Santagata Dora²⁴,Le Long P.⁴,Iafrate Anthony John²⁴,Heist Rebecca S.¹²^ORCID,Ritterhouse Lauren R.²⁴,Lennerz Jochen K.²⁴^ORCID

Affiliation:

1. Massachusetts General Hospital Cancer Center, Boston, MA

2. Harvard Medical School, Boston, MA

3. Partners Health Specialty Pharmacy, Boston, MA

4. Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, MA

5. Department of Radiology, Massachusetts General Hospital, Boston, MA

6. Interventional Pulmonology, Massachusetts General Hospital, Boston, MA

7. Department of Pathology, Massachusetts General Hospital, Boston, MA

Abstract

A workflow involving radiology, pathology, pharmacy, and oncology reduced time between biopsy and osimertinib.

Publisher

American Society of Clinical Oncology (ASCO)